UroGen Pharma’s (URGN) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a report published on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock.

UroGen Pharma Stock Performance

Shares of UroGen Pharma stock opened at $10.56 on Tuesday. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The business has a 50-day moving average price of $10.79 and a two-hundred day moving average price of $12.26. UroGen Pharma has a 1-year low of $9.78 and a 1-year high of $20.70. The company has a market cap of $247.63 million, a P/E ratio of -3.35 and a beta of 1.08.

Insider Transactions at UroGen Pharma

In other news, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the transaction, the insider now owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This represents a 3.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On UroGen Pharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in UroGen Pharma by 2.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock valued at $14,667,000 after acquiring an additional 36,084 shares in the last quarter. Vestal Point Capital LP lifted its position in UroGen Pharma by 307.5% in the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock valued at $17,360,000 after acquiring an additional 1,230,000 shares in the last quarter. Stonepine Capital Management LLC lifted its position in UroGen Pharma by 15.7% in the 4th quarter. Stonepine Capital Management LLC now owns 324,324 shares of the company’s stock valued at $3,454,000 after acquiring an additional 43,979 shares in the last quarter. Toronto Dominion Bank bought a new position in UroGen Pharma in the 4th quarter valued at about $18,628,000. Finally, RTW Investments LP lifted its position in UroGen Pharma by 1.3% in the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock valued at $40,841,000 after acquiring an additional 47,447 shares in the last quarter. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.